Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA1 | Q13131 | 7/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 0.81 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.79 |
| ▸ | PLK4 | O00444 | 2/20 | 0.77 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.77 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116298 | 1.00 | PRKAA1 (1.00) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL28427292 | 1.00 | PRKAA1 (1.00) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| Trifluoroacetic Acid SCHEMBL29281305 | 0.95 | PRKAA1 (0.90) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL2088460 | 0.94 | PRKAA1 (0.90) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL20805259 | 0.93 | PRKAA1 (0.86) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL28435599 | 0.91 | PRKAA1 (0.84) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL29856566 | 0.91 | KDR (0.86) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL14047978 | 0.91 | KDR (0.86) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL28435601 | 0.91 | PRKAA1 (0.84) | PRKAA1PRKAA2KDRTLK2PDGFRB | |
| SCHEMBL13960774 | 0.91 | PRKAA1 (0.83) | PRKAA1PRKAA2KDRTLK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435059-B2 | AMP-activated protein kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-119836420-A | 2-Indolone compounds as VEGFR and PKa dual-target inhibitors, preparation method and application thereof | 远森制药（杭州）有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250009893-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2025007853-A1 | 2-INDOLINONE COMPOUND SERVING AS VEGFR AND PKA DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 远森制药（杭州）有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-118159295-A | Dendrimer conjugates and methods of use thereof | 阿什瓦塔治疗股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4351652-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261504-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4069308-A2 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115103690-A | Dendrimer compositions and methods for drug delivery to the eye | 阿什瓦塔治疗股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220289707-A1 | AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435059-B2 | AMP-activated protein kinase inhibitors and methods of making and using the same | PRKAA1, PRKAA2, PRKAG1 | PRKAA1 1/4885PRKAA2 2/4885KDR 1564/4885 |
| US-20250009893-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | PAICS, CD47, CD44 | PRKAA1 3833/4885PRKAA2 3668/4885KDR 756/4885 |
| US-20220289707-A1 | AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | PRKAA1, PRKAA2, PRKAG1 | PRKAA1 1/4885PRKAA2 2/4885KDR 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.